First clinical trial with iohexol in myelography.
This is a report of the first clinical trial with iohexol in lumbar myelography. The investigation was carried out as an open, non-comparative study in 30 patients and was part of a multicentre trial. Iohexol doses of 10 to 15 ml (180 mg I/ml) were used and clinical and laboratory tests were performed before and during 48 h after myelography. Spinal repuncture 6 or 24 h after myelography was done in all patients. Only minor side effects of temporary duration were recorded in 8 patients. No seizures or spikes on EEG were seen. There was no significant increase in CSF parameters such as white cell counts, protein or IgG.
D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D003287:Contrast Media / Q000009:adverse effects; D003402:Creatine Kinase / Q000134:cerebrospinal fluid; D004341:Drug Evaluation; D004569:Electroencephalography; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D007527:Isoenzymes; D008161:Lumbosacral Region; D008297:Male; D009192:Myelography / Q000379:methods*; D009325:Nausea / Q000139:chemically induced; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D002556:Cerebrospinal Fluid Proteins; D003287:Contrast Media; D007463:Iodobenzoates; D007527:Isoenzymes; D014283:Triiodobenzoic Acids; D007472:Iohexol; D003402:Creatine Kinase